Bioselection to assess tumor response after induction chemotherapy has been introduced as an alternative treatment strategy to total laryngectomy for patients with advanced larynx squamous cell carcinoma (LSCC). Tumor-infiltrating lymphocytes (TILs) have proven to serve as prognostic biomarkers in head and neck cancer but have not been evaluated as a way to select patients for treatment paradigms. The aim of this study is to evaluate the role of pretreatment TILs in patients with advanced LSCC undergoing the bioselection paradigm.
Study Design
Retrospective study.
Setting
Tertiary care hospital.
Methods
Patients with advanced LSCC treated with bioselection and available tissue were included (N = 76). Patients were stratified into CD8-low and CD8-high cohorts by using the median TIL count. Kaplan-Meier survival analysis and multivariate cox regression were performed with SPSS version 26 (IBM).
Results
After controlling for tobacco use, tumor site, and stage, a high CD8 TIL count was an independent predictor of improved 5-year disease-specific survival (hazard ratio, 0.17 [95% CI, 0.03-0.84]; P = .03). CD8 TIL counts did not predict response to induction chemotherapy; however, subgroup analysis of patients treated with chemoradiation therapy revealed that CD8 TIL count was significantly associated with degree of response (P = .012).
Conclusion
These findings support prior data published by our group showing that TILs are predictive of disease-specific survival in patients with head and neck cancer. CD8 TIL counts were significantly associated with degree of clinical response after induction chemotherapy. These results suggest that pretreatment assessment of tumor-infiltrating CD8 cells could be useful in selecting patients.
Surveillance, Epidemiology, and End Results. Program research data (1973-2015). National Cancer Institute. Released April2018 (based on the November2017 submission). http://www.seer.cancer.gov
2.
HartlDMFerlitoABrasnuDF, et al. Evidence-based review of treatment options for patients with glottic cancer. Head Neck. 2011;33(11):1638-1648.
3.
WolfGT.Integrating surgery into treatment paradigms for organ preservation: tailoring treatment to biology improves outcomes. Int J Radiat Oncol Biol Phys. 2007;69(2):S4-S7.
4.
ForastiereAAGoepfertHMaorM, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091-2098.
5.
WolfGTFisherSGHongWK, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685-1690.
6.
MegwaluUCSikoraAG.Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(9):855-860.
7.
HoffmanHTPorterKKarnellLH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116(9)(pt 2, suppl 111):1-13.
8.
WolfGTBellileEEisbruchA, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017;143(4):355-366.
9.
UrbaSWolfGEisbruchA, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24(4):593-598.
10.
BradfordCRWolfGTCareyTE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121(5):534-538.
11.
de BreeRWolfGTde KeizerB, et al. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: from physical examination to modern imaging techniques and beyond. Head Neck. 2017;39(11):2329-2349.
12.
HoesliRBirkelandACRoskoAJ, et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018;77:83-89.
13.
MannJESmithJDBirkelandAC, et al. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunol Immunother. 2019;68(2):213-220.
14.
FerrisRLHuntJLFerroneS.Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33(2):113-133.
15.
Concha-BenaventeFSrivastavaRFerroneSFerrisRL.Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 2016;58:52-58.
16.
MeissnerMReichertTEKunkelM, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005;11(7):2552-2560.
17.
SpectorMEBellileEAmlaniL, et al. Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2019;145(11):1012-1019.
18.
NguyenNBellileEThomasD, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(7):1074-1084.
19.
BradfordCRKumarBBellileE, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014;124(1):179-187.
20.
Heft NealMEHaringCTMannJEBrennerJCSpectorMESwiecickiPL.Novel immunotherapeutic approaches in head and neck cancer. J Cancer Metastasis Treat. 2019;5:76.
21.
GrandalBEvrevinCLaasE, et al. Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Cancers (Basel). 2020;12(12):3681.
22.
ParkYHLalSLeeJE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020;11(1):6175.
23.
EnsleyJFJacobsJRWeaverA, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984;54(5):811-814.
24.
SpauldingMBFischerSGWolfGT.Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol. 1994;12(8):1592-1599.
25.
QianDWangYZhaoG, et al. Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(2):319-328.
26.
WestNRMilneKTruongPTMacphersonNNelsonBHWatsonPH.Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126.
27.
BaxevanisCNDedoussisGVPapadopoulosNGMissitzisIStathopoulosGPPapamichailM.Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 1994;74(4):1275-1282.
28.
RabinowichHCohenRBrudermanISteinerZKlajmanA.Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987;47(1):173-177.
29.
TopalianSLSolomonDRosenbergSA.Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142(10):3714-3725.
30.
DemariaSVolmMDShapiroRL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025-3030.
31.
BauerJAKumarBCordellKG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):S106-S108.
32.
YipHTChopraRChakrabartiR, et al. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg. 2006;132(3):317-326.
33.
de BiasiARVillena-VargasJAdusumilliPS.Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 2014;20(21):5384-5391.
34.
TranLAllenCTXiaoR, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res. 2017;5(12):1141-1151.
35.
WaksAGStoverDGGuerrieroJL, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clin Cancer Res. 2019;25(15):4644-4655.
36.
PelekanouVCarvajal-HausdorfDEAltanM, et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017;19(1):91.
37.
SalgadoRDenkertCDemariaS, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-271.
